Dragonfly and Gilead to Explore DF1001 HER-2 TriNKET with Trodelvy in Cancer

CAR-T Digest - August 2020

15 Feb 2024: Dragonfly and Gilead to Explore DF1001 HER-2 TriNKET with Trodelvy in Cancer

Dragonfly Therapeutics has initiated a clinical collaboration to assess DF1001, a HER-2 immune engager developed via their TriNKET technology platform, alongside Trodelvy, a Trop-2-directed antibody-drug conjugate (ADC) from Gilead, for treating metastatic breast cancer (mBC) and non-small cell lung cancer (NSCLC)
DF1001, an investigational first-in-class drug candidate, targets natural killer (NK) cells and T-cell activation signals, offering potential for stimulating anti-tumor immunity in patients with advanced solid HER-2 positive tumors
DF1001, the first of eight Dragonfly-developed drugs in clinical trials, has exhibited clinical benefit in mBC, NSCLC, and colorectal cancer (CRC), demonstrating promising pharmacodynamic activity and tolerability in Phase 1 trials
This collaboration aims to capitalize on the synergistic potential of DF1001 and Trodelvy, as supported by preclinical data, to enhance treatment efficacy in these cancer types
With operational control of the study, Dragonfly plans to commence patient treatment in Q2 2024 across various clinical trial sites globally, with additional sites expected to open in North America, Europe, and the Asia Pacific region in 2024